MedTrace Logo

TLA in Children With Moderate to Severe Atopic Eczema (TLA4AE)

NCT03795506 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2024-01-08

No results posted yet for this study

Summary

This is a single centre randomised, placebo-controlled phase 2 study in which 96 children age 4 to 16 years with moderate to severe, longstanding allergic eczema will be enrolled.

Conditions

  • Atopic Dermatitis Eczema

Interventions

DEVICE

Nocturnal Temperature controlled Laminar Airflow (TLA) Treatment

12 weeks of overnight treatment with active TLA device

DEVICE

Placebo TLA Device

12 weeks of overnight use of placebo TLA device

Sponsors & Collaborators

  • JP Moulton Charitable Foundation

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Claudia Gore, MD PhD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-08
Primary Completion
2024-12-31
Completion
2025-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03795506 on ClinicalTrials.gov